Bevacizumab terminates HOXB9 induced tumor proliferation
Project/Area Number |
25293292
|
Research Category |
Grant-in-Aid for Scientific Research (B)
|
Allocation Type | Partial Multi-year Fund |
Section | 一般 |
Research Field |
Digestive surgery
|
Research Institution | Keio University |
Principal Investigator |
Kitagawa Yuko 慶應義塾大学, 医学部, 教授 (20204878)
|
Co-Investigator(Kenkyū-buntansha) |
Hasegawa Hirotoshi 慶應義塾大学, 医学部, 准教授 (00218455)
Hayashida Tetsu 慶應義塾大学, 医学部, 講師 (80327543)
Okabayashi Koji 慶應義塾大学, 医学部, 助教 (00338063)
|
Project Period (FY) |
2013-04-01 – 2016-03-31
|
Project Status |
Completed (Fiscal Year 2015)
|
Budget Amount *help |
¥17,940,000 (Direct Cost: ¥13,800,000、Indirect Cost: ¥4,140,000)
Fiscal Year 2015: ¥6,110,000 (Direct Cost: ¥4,700,000、Indirect Cost: ¥1,410,000)
Fiscal Year 2014: ¥6,110,000 (Direct Cost: ¥4,700,000、Indirect Cost: ¥1,410,000)
Fiscal Year 2013: ¥5,720,000 (Direct Cost: ¥4,400,000、Indirect Cost: ¥1,320,000)
|
Keywords | 大腸癌 / HOXB9 / ベバシズマブ / 血管新生 / インターロイキン6 / IL-6 |
Outline of Final Research Achievements |
Homeobox B9 (HOXB9), a transcriptional factor, regulates developmental processes and tumor progression and has recently been recognized as a strong angiogenic factor. This study aimed to investigate the role of HOXB9 in tumorigenesis and angiogenesis. Bevacizumab, an anti-VEGF antibody, remarkably suppressed tumor proliferation by inhibiting angiogenesis in HOXB9-overexpressing xenografts, and it improved overall survival and provided prolonged progression-free survival in HOXB9-overexpressing patients. HOXB9 promotes the secretion of angiogenic factors, including VEGF, to induce tumor proliferation through microenvironmental communication via IL6 signaling; moreover, silencing of VEGF or IL6 terminates microenvironmental crosstalk. Thus, HOXB9 and IL6 may be surrogate markers for bevacizumab treatment.
|
Report
(4 results)
Research Products
(6 results)
-
[Journal Article] Comparative effectiveness of neoadjuvant therapy for HER2-positive breast cancer: A network meta-analysis.2014
Author(s)
Aiko Nagayama, Tetsu Hayashida, Hiromitsu Jinno, Maiko Takahashi, Tomoko Seki, Akiko Matsumoto, Takeshi Murata, Hutan Ashrafian, Thanos Athanasiou, Koji Okabayashi, and Yuko Kitagawa
-
Journal Title
Journal of the National Cancer Institute
Volume: 106(9)
Issue: 9
DOI
Related Report
Peer Reviewed / Acknowledgement Compliant
-
-
[Journal Article] Bevacizumab terminates homeobox B9-induced tumor proliferation by silencing microenvironmental communication.2014
Author(s)
Yoshinori Hoshino, Tetsu Hayashida, Akira Hirata, Hidena Takahashi, Naokazu Chiba, Mitsuyo Ohmura, Masatoshi Wakui, Hiromitsu Jinno, Hirotoshi Hasegawa, Shyamala Maheswaran, Makoto Suematsu, Yuko Kitagawa,
-
Journal Title
Molecular Cancer
Volume: 13(1)
Issue: 1
Pages: 102-102
DOI
Related Report
Peer Reviewed / Open Access / Acknowledgement Compliant
-
-
-